SCHEDULE 13G/A: RTW Investments Maintains Significant 6.0% Stake in Axsome Therapeutics
Beneficial Ownership Report
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a continued beneficial ownership of 6.0% in Axsome Therapeutics, Inc. common stock.
Summary
- RTW Investments, LP and Roderick Wong, M.D. collectively reported beneficial ownership of 2,922,729 shares of Axsome Therapeutics, Inc. common stock.
- This ownership represents 6.0% of the company's outstanding common stock.
- The percentage is calculated based on 48,765,403 shares outstanding as of February 11, 2025, as reported in Axsome Therapeutics' Annual Report on Form 10-K.
- The Reporting Persons, RTW Investments and Dr. Wong, hold shared voting and shared dispositive power over all 2,922,729 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Axsome Therapeutics.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Axsome Therapeutics' future performance or strategic direction.
Management Comments
- Roderick Wong, M.D., Managing Partner of RTW Investments, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing is a routine disclosure of beneficial ownership by an institutional investor in a publicly traded biotechnology company. It reflects an ongoing investment position rather than a new strategic move within the industry.
Stakeholder Impact
- Shareholders: The continued significant stake held by an institutional investor like RTW Investments may be viewed as a sign of confidence in Axsome Therapeutics, potentially influencing investor sentiment positively.
Key Dates
| Date | Description |
|---|---|
| 02/11/2025 | Date as of which 48,765,403 shares outstanding were reported in the Company's Annual Report on Form 10-K. |
| 03/31/2025 | Date of event which required the filing of this statement. |
| 05/15/2025 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
Axsome Therapeutics, RTW Investments, Beneficial Ownership, Schedule 13G, Common Stock, Investment Firm, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.